Cellular Immunotherapy for Ovarian Cancer

This trial tests a new treatment called Innocell Autologous Cellular Immunotherapy for women with recurrent ovarian cancer. The main goal is to assess the treatment's safety and the immune system's response. This trial targets women with a confirmed diagnosis of advanced epithelial ovarian cancer who have previously undergone treatments like chemotherapy and require a new option. Participants must have at least two measurable or detectable cancer areas. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial requires that you stop taking systemic steroids or any other immunosuppressive therapy at least 14 days before starting the treatment. If you're on any other approved systemic therapy, you need to stop it 3 weeks before starting the trial.

Research shows that Innocell Autologous Cellular Immunotherapy is being tested for safety in people with recurring epithelial ovarian cancer. As this trial is in its early stages, the primary goal is to assess how well participants tolerate the treatment and identify any side effects.

Although no previous human trials have provided safety data for Innocell, the FDA's approval for human testing indicates promise in earlier lab and animal studies. This suggests that major safety concerns were likely addressed before the trial began.

Unlike the standard treatments for ovarian cancer, which often involve surgery and chemotherapy, Innocell Autologous Cellular Immunotherapy uses a unique approach by harnessing the body's own immune cells. Researchers are excited about this treatment because it involves engineering a patient's immune cells to better recognize and attack cancer cells, potentially leading to a more targeted and effective response. Additionally, the use of the CpG 1018 adjuvant in conjunction with this therapy may enhance the immune system's ability to fight the cancer more aggressively. This personalized approach could offer new hope for patients who have limited options with traditional therapies.

Research has shown that Innocell Autologous Cellular Immunotherapy, which participants in this trial will receive, might be promising for treating recurring ovarian cancer. In earlier studies, combining this treatment with another drug led to better results than using the other drug alone, with a 31.4% response rate compared to 12.2%. This suggests that Innocell might help the immune system fight cancer more effectively. Although data remains limited, early results offer hope for improving treatment outcomes in ovarian cancer.¹²³⁶⁷